Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fate Therapeutics

1.39
-0.2450-14.98%
Post-market: 1.440.0500+3.60%19:48 EDT
Volume:2.34M
Turnover:3.42M
Market Cap:160.31M
PE:-0.96
High:1.63
Open:1.61
Low:1.38
Close:1.64
52wk High:3.50
52wk Low:0.6611
Shares:115.33M
Float Shares:100.80M
Volume Ratio:0.53
T/O Rate:2.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4503
EPS(LYR):-1.6384
ROE:-52.11%
ROA:-24.66%
PB:0.61
PE(LYR):-0.85

Loading ...

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Oct 03

Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 62% over the previous year

Simply Wall St.
·
Oct 01

Fate Therapeutics Announces New Employee Inducement Awards Under Nasdaq Rule 5635(c)(4)

Reuters
·
Sep 04

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Sep 04

Fate Therapeutics Inc : Leerink Partners Cuts Target Price to $7 From $12

THOMSON REUTERS
·
Sep 03

Fate Therapeutics Inc. to Participate in Cantor Global Healthcare Conference 2025

Reuters
·
Aug 25

Fate Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
Aug 25

BofA Securities Adjusts Fate Therapeutics Price Target to $2 From $2.20, Maintains Neutral Rating

MT Newswires Live
·
Aug 15

Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Aug 13

Fate Therapeutics Q2 EPS $(0.29) Beats $(0.34) Estimate, Sales $1.907M Beat $1.011M Estimate

Benzinga
·
Aug 13

Fate Therapeutics Reports Q2 2025 Revenue of $1.9M, Operating Expenses at $38.9M; Cash Position at $248.9M

Reuters
·
Aug 13

Fate Therapeutics Secures FDA Approval for IND Application of FT836 for Conditioning-Free Solid Tumor Treatment

Reuters
·
Aug 13

Fate Therapeutics Inc - Extends Operating Runway Through Ye27

THOMSON REUTERS
·
Aug 13

Fate Therapeutics Q2 Net Income USD -34.07 Million

THOMSON REUTERS
·
Aug 13

Fate Therapeutics Q2 Income From Operations USD -36.968 Million

THOMSON REUTERS
·
Aug 13

Fate Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
Aug 08

BRIEF-Fate Therapeutics Reports New Employee Inducement Awards

Reuters
·
Aug 06

Valamehr Bahram, President and CEO, Reports Disposal of Common Shares of Fate Therapeutics Inc

Reuters
·
Aug 06

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 06

Fate Therapeutics Inc. Files Initial Statement of Beneficial Ownership; RedCo II Master Fund, L.P. Named as Beneficial Owner

Reuters
·
Jul 04